The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform
Allan S. Kaplan - One of the best experts on this subject based on the ideXlab platform.
-
activity of a 0 05 triamcinolone acetonide laurocapram formulation double blind randomized comparison with standard 0 1 triamcinolone acetonide creams and with mild class vi to potent class iii topical corticosteroids
Current Therapeutic Research-clinical and Experimental, 2001Co-Authors: Allen Cato, Lynda Sutton, George N. Manning, Allan S. KaplanAbstract:Abstract Background: The addition of laurocapram, a skin penetration enhancer, to a 0.05% triamcinolone acetonide (TA) cream has been shown to improve the activity of the corticosteroid. Objective: The purpose of these studies was to compare the activity of a 0.05% TA/laurocapram formulation (TNX) with that of standard 0.1% TA cream formulations and 3 topical corticosteroids classified as mild to potent—fluocinolone acetonide, Amcinonide, and mometasone furoate. Methods: Sixty-one healthy adult subjects participated in 2 double-blind, randomized, single-point vasoconstriction studies. In each study, sites on subjects' forearms were exposed to the topical corticosteroid formulation for 6 or 16 hours. The degree of vasoconstriction (ie, skin blanching), a surrogate measure of the activity of the corticosteroid, was assessed 2 hours after the end of the exposure period using a 4-point scale (0 = none, 1=mild, 2=moderate, 3=marked). Results: The vasoconstriction activity of TNX was significantly greater than that of 4 marketed 0.1% TA topical formulations ( P ≤ 0.05), which are classified as mild to mid-strength corticosteroids. The activity of TNX was also greater than that of 0.01% and 0.025% fluocinolone acetonide and 0.1% Amcinonide ( P = 0.05), classified as mild, mid-strength, and potent agents, respectively, and similar to that of 0.1% mometasone furoate, a Class IV mid-strength agent. Conclusions: Based on the correlation between the vasoconstriction activity of corticosteroids and their clinical activity, the results suggest that the addition of laurocapram will enhance the clinical activity of corticosteroids and hence may improve treatments for corticosteroid-responsive dermatoses. Moreover, the TA/laurocapram formulation can be differentiated therapeutically from conventional TA creams.
Allen Cato - One of the best experts on this subject based on the ideXlab platform.
-
activity of a 0 05 triamcinolone acetonide laurocapram formulation double blind randomized comparison with standard 0 1 triamcinolone acetonide creams and with mild class vi to potent class iii topical corticosteroids
Current Therapeutic Research-clinical and Experimental, 2001Co-Authors: Allen Cato, Lynda Sutton, George N. Manning, Allan S. KaplanAbstract:Abstract Background: The addition of laurocapram, a skin penetration enhancer, to a 0.05% triamcinolone acetonide (TA) cream has been shown to improve the activity of the corticosteroid. Objective: The purpose of these studies was to compare the activity of a 0.05% TA/laurocapram formulation (TNX) with that of standard 0.1% TA cream formulations and 3 topical corticosteroids classified as mild to potent—fluocinolone acetonide, Amcinonide, and mometasone furoate. Methods: Sixty-one healthy adult subjects participated in 2 double-blind, randomized, single-point vasoconstriction studies. In each study, sites on subjects' forearms were exposed to the topical corticosteroid formulation for 6 or 16 hours. The degree of vasoconstriction (ie, skin blanching), a surrogate measure of the activity of the corticosteroid, was assessed 2 hours after the end of the exposure period using a 4-point scale (0 = none, 1=mild, 2=moderate, 3=marked). Results: The vasoconstriction activity of TNX was significantly greater than that of 4 marketed 0.1% TA topical formulations ( P ≤ 0.05), which are classified as mild to mid-strength corticosteroids. The activity of TNX was also greater than that of 0.01% and 0.025% fluocinolone acetonide and 0.1% Amcinonide ( P = 0.05), classified as mild, mid-strength, and potent agents, respectively, and similar to that of 0.1% mometasone furoate, a Class IV mid-strength agent. Conclusions: Based on the correlation between the vasoconstriction activity of corticosteroids and their clinical activity, the results suggest that the addition of laurocapram will enhance the clinical activity of corticosteroids and hence may improve treatments for corticosteroid-responsive dermatoses. Moreover, the TA/laurocapram formulation can be differentiated therapeutically from conventional TA creams.
George N. Manning - One of the best experts on this subject based on the ideXlab platform.
-
activity of a 0 05 triamcinolone acetonide laurocapram formulation double blind randomized comparison with standard 0 1 triamcinolone acetonide creams and with mild class vi to potent class iii topical corticosteroids
Current Therapeutic Research-clinical and Experimental, 2001Co-Authors: Allen Cato, Lynda Sutton, George N. Manning, Allan S. KaplanAbstract:Abstract Background: The addition of laurocapram, a skin penetration enhancer, to a 0.05% triamcinolone acetonide (TA) cream has been shown to improve the activity of the corticosteroid. Objective: The purpose of these studies was to compare the activity of a 0.05% TA/laurocapram formulation (TNX) with that of standard 0.1% TA cream formulations and 3 topical corticosteroids classified as mild to potent—fluocinolone acetonide, Amcinonide, and mometasone furoate. Methods: Sixty-one healthy adult subjects participated in 2 double-blind, randomized, single-point vasoconstriction studies. In each study, sites on subjects' forearms were exposed to the topical corticosteroid formulation for 6 or 16 hours. The degree of vasoconstriction (ie, skin blanching), a surrogate measure of the activity of the corticosteroid, was assessed 2 hours after the end of the exposure period using a 4-point scale (0 = none, 1=mild, 2=moderate, 3=marked). Results: The vasoconstriction activity of TNX was significantly greater than that of 4 marketed 0.1% TA topical formulations ( P ≤ 0.05), which are classified as mild to mid-strength corticosteroids. The activity of TNX was also greater than that of 0.01% and 0.025% fluocinolone acetonide and 0.1% Amcinonide ( P = 0.05), classified as mild, mid-strength, and potent agents, respectively, and similar to that of 0.1% mometasone furoate, a Class IV mid-strength agent. Conclusions: Based on the correlation between the vasoconstriction activity of corticosteroids and their clinical activity, the results suggest that the addition of laurocapram will enhance the clinical activity of corticosteroids and hence may improve treatments for corticosteroid-responsive dermatoses. Moreover, the TA/laurocapram formulation can be differentiated therapeutically from conventional TA creams.
Lynda Sutton - One of the best experts on this subject based on the ideXlab platform.
-
activity of a 0 05 triamcinolone acetonide laurocapram formulation double blind randomized comparison with standard 0 1 triamcinolone acetonide creams and with mild class vi to potent class iii topical corticosteroids
Current Therapeutic Research-clinical and Experimental, 2001Co-Authors: Allen Cato, Lynda Sutton, George N. Manning, Allan S. KaplanAbstract:Abstract Background: The addition of laurocapram, a skin penetration enhancer, to a 0.05% triamcinolone acetonide (TA) cream has been shown to improve the activity of the corticosteroid. Objective: The purpose of these studies was to compare the activity of a 0.05% TA/laurocapram formulation (TNX) with that of standard 0.1% TA cream formulations and 3 topical corticosteroids classified as mild to potent—fluocinolone acetonide, Amcinonide, and mometasone furoate. Methods: Sixty-one healthy adult subjects participated in 2 double-blind, randomized, single-point vasoconstriction studies. In each study, sites on subjects' forearms were exposed to the topical corticosteroid formulation for 6 or 16 hours. The degree of vasoconstriction (ie, skin blanching), a surrogate measure of the activity of the corticosteroid, was assessed 2 hours after the end of the exposure period using a 4-point scale (0 = none, 1=mild, 2=moderate, 3=marked). Results: The vasoconstriction activity of TNX was significantly greater than that of 4 marketed 0.1% TA topical formulations ( P ≤ 0.05), which are classified as mild to mid-strength corticosteroids. The activity of TNX was also greater than that of 0.01% and 0.025% fluocinolone acetonide and 0.1% Amcinonide ( P = 0.05), classified as mild, mid-strength, and potent agents, respectively, and similar to that of 0.1% mometasone furoate, a Class IV mid-strength agent. Conclusions: Based on the correlation between the vasoconstriction activity of corticosteroids and their clinical activity, the results suggest that the addition of laurocapram will enhance the clinical activity of corticosteroids and hence may improve treatments for corticosteroid-responsive dermatoses. Moreover, the TA/laurocapram formulation can be differentiated therapeutically from conventional TA creams.
A Brouwer - One of the best experts on this subject based on the ideXlab platform.
-
steroid hormonal bioactivities culprit natural and synthetic hormones and other emerging contaminants in waste water measured using bioassays and uplc tq ms
Science of The Total Environment, 2018Co-Authors: Corine J Houtman, Rob Ten Broek, A BrouwerAbstract:Emission of compounds with biological activities from waste water treatment plant (WWTP) effluents into surface waters is a topic of concern for ecology and drinking water quality. We investigated the occurrence of hormone-like activities in waste water sample extracts from four Dutch WWTPs and pursued to identify compounds responsible for them. To this aim, in vitro reporter gene bioassays for androgenic, anti-androgenic, estrogenic, glucocorticoid and progestogenic activity and a UPLC-tQ-MS target analysis method for 25 steroid hormones used in high volumes in pharmacy were applied. Principal component analysis of the data was performed to further characterize the detected activities and compounds. All five types of activities tested were observed in the WWTP samples. Androgenic and estrogenic activities were almost completely removed during WW treatment, anti-androgenic activity was only found in treated WW. Glucocorticoid and progestogenic activities persisted throughout the treatment. The androgenic activity in both influent could predominantly be attributed to the presence of androstenedione and testosterone. Anti-androgenic activity was explained by the presence of cyproterone acetate. The glucocorticoid activity in influent was fully explained by prednicarbate, triamcinolone acetonide, dexamethasone and Amcinonide. In effluent however, detected hormones could only explain 10-32% of the activity, indicating the presence of unknown glucocorticoids or their metabolites in effluent. Progesterone and levonorgestrel could explain the observed progestogenic activity. The principle component analysis confirmed the way in which hormones fit in the spectrum of other emerging contaminants concerning occurrence and fate in WWTPs.